Skip to content

Real World Data Collection on the INSPIRIS RESILIA Aortic Valve

A Prospective, Observational Registry Study Designed to Collect Real-world Hemodynamic and Clinical Outcomes of the INSPIRIS RESILIA Aortic Valve

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07120048
Acronym
INDICATE
Enrollment
500
Registered
2025-08-13
Start date
2025-07-30
Completion date
2026-12-01
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Valve Disease

Brief summary

Collect real-world data on hemodynamic and clinical outcomes of the INSPIRIS RESILIA Aortic Valve, Model 11500A, in subjects requiring replacement of their native or prosthetic aortic valve as the only heart valve procedure during the index procedure, with or without other concomitant procedures.

Detailed description

Subjects in the INDICATE registry study will be enrolled at up to 20 sites in Germany. Up to 500 subjects will be implanted with the INSPIRIS RESILIA Aortic Valve in this registry.

Interventions

Surgical replacement of the aortic valve with the Edwards INSPIRIS RESILIA Aortic Valve

Sponsors

Edwards Lifesciences
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients requiring an aortic valve replacement using the INSPIRIS RESILIA aortic valve according to its intended purpose 2. Patients with standard-of-care pre-procedure imaging evaluation (echocardiography and CT) data available 3. Age ≥ 18 years 4. Provision of written informed consent

Exclusion criteria

1. Active endocarditis/myocarditis or endocarditis/myocarditis within 3 months prior to the scheduled aortic valve replacement surgery 2. Emergency procedure 3. Patients requiring a non-aortic heart valve procedure during the index procedure

Design outcomes

Primary

MeasureTime frameDescription
Subject's average mean gradient measurement over timePrior to discharge (an average of 7 to 10 days after surgery) and at 3 monthsMean gradient is the average flow of blood through the aortic valve measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. In general, a higher value is considered worse, and a lower value is considered better but the value is dependent on the size and type of valve.
Subject's average peak gradient measurement over timePrior to discharge (an average of 7 to 10 days after surgery) and at 3 monthsPeak gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. In general, a higher valve is considered worse, and a lower value is considered better, but the value is dependent on the size and type of valve.
Amount of aortic transvalvular regurgitation in subjects over timePrior to discharge (an average of 7 to 10 days after surgery) and at 3 monthsValvular regurgitation occurs when the valve in the heart does not close tightly allowing some of the blood that was pumped out of the heart to leak back into it. Valvular regurgitation is evaluated by echocardiography over time. It is assessed by four categories, which are "no/trace leak", "a mild leak", "a moderate leak", and "a severe leak". A severe leak indicates a worsening outcome.
Amount of aortic paravalvular regurgitation in subjects over timePrior to discharge (an average of 7 to 10 days after surgery) and at 3 monthsParavalvular leak refers to blood flowing through a channel between the implanted artificial valve and the cardiac tissue as a result of inappropriate sealing. Paravalvular leak is evaluated by echocardiography over time. It is assessed by four categories, which are "no/trace leak", "a mild leak", "a moderate leak", and "a severe leak". A severe leak indicates a worsening outcome.

Secondary

MeasureTime frameDescription
Subject's New York Heart Association (NYHA) functional classification at 3 months as compared to baseline.Baseline and 3 monthsThe New York Heart Association (NYHA) functional classification system relates symptoms to everyday activities and the patient's quality of life. Class I. No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath). Class II. Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath). Class III. Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea. Class IV. Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.

Countries

Germany

Contacts

CONTACTSabrina Hundt, PhD
sabrina_hundt@edwards.com+49 151 67550601
PRINCIPAL_INVESTIGATORTorsten Doenst, Prof. Dr. med.

Jena University Hospital, University of Jena

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 23, 2026